Dyne Therapeutics wins FDA IND clearance for FORCE-platform candidate DYNE-302 in FSHD

Dyne Therapeutics, a Waltham, Massachusetts clinical-stage company developing therapies for genetically driven muscle diseases, announced on 28 July 2026 that the US Food and Drug Administration has cleared its Investigational New Drug (IND) application for DYNE-302 in facioscapulohumeral muscular dystrophy (FSHD).

DYNE-302 is the company's third programme to enter clinical development using its FORCE platform, which is designed to deliver therapeutics to muscle with the goal of functional improvement in rare neuromuscular disease. The IND clearance opens the path to a first-in-human study in FSHD, a progressive muscle-wasting disorder with no approved disease-modifying treatments.

Source: BioSpace / GlobeNewswire, 28 July 2026.